Tower Research Capital LLC (Trc) Arcus Biosciences, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.29 Billion
- Q1 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,973 shares of RCUS stock, worth $28,748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,973
Previous 7,183
58.61%
Holding current value
$28,748
Previous $106,000
78.3%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding RCUS
# of Institutions
198Shares Held
61.8MCall Options Held
85.8KPut Options Held
86.4K-
Black Rock Inc. New York, NY9.76MShares$94.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$63.4 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$49.6 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$35.7 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$27.7 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $698M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...